Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ZHENTAO ZHANG

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1558652826
CMS profile
777976
Location
FORT WAYNE, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$46,648.31

156 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 4; records 51–100 of 156 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ZHENTAO ZHANG

NPI 1558652826 · CMS profile ID 777976

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

FORT WAYNE, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 156 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1558652826?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ZHENTAO ZHANG, NPI 1558652826, CMS profile ID 777976. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 156 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1558652826?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). ZHENTAO ZHANG, NPI 1558652826, CMS profile ID 777976. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 156 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1558652826?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
ZHENTAO ZHANG, NPI 1558652826, CMS profile ID 777976, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 156 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1558652826?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

156 matching records · $46,648.31 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 156 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 156.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
E.R. Squibb & Sons, L.L.C. $142.8608/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101429408 CMS
E.R. Squibb & Sons, L.L.C. $155.2008/20/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101429458 CMS
PFIZER INC. $20.1308/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131342475 CMS
Novartis Pharmaceuticals Corporation $11.2908/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087352510 CMS
PFIZER INC. $26.5508/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131903391 CMS
Genentech USA, Inc. $20.4208/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133136887 CMS
Merck Sharp & Dohme LLC $20.0708/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141567590 CMS
PFIZER INC. $12.2108/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132024209 CMS
E.R. Squibb & Sons, L.L.C. $17.8407/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101429372 CMS
E.R. Squibb & Sons, L.L.C. $5.8507/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101429376 CMS
Aveo Pharmaceuticals, Inc. $1,138.0007/23/2024 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143488931 CMS
E.R. Squibb & Sons, L.L.C. $14.9107/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101429374 CMS
ADC Therapeutics America, Inc. $120.6007/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1121189314 CMS
PFIZER INC. $34.7507/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131348949 CMS
Novartis Pharmaceuticals Corporation $23.8307/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087352508 CMS
Celgene Corporation $21.1807/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101136212 CMS
Gilead Sciences, Inc. $16.7407/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133799896 CMS
Novartis Pharmaceuticals Corporation $14.4207/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087352506 CMS
Aveo Pharmaceuticals, Inc. $91.4006/28/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143488908 CMS
E.R. Squibb & Sons, L.L.C. $118.2606/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101429382 CMS
PFIZER INC. $18.3706/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131811764 CMS
PFIZER INC. $3.4206/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131811766 CMS
PFIZER INC. $1,868.6506/23/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131697311 CMS
PFIZER INC. $17.9706/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131697309 CMS
E.R. Squibb & Sons, L.L.C. $8.6706/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101429368 CMS
PFIZER INC. $4,250.0006/21/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131697313 CMS
E.R. Squibb & Sons, L.L.C. $25.3506/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101429360 CMS
PFIZER INC. $66.9506/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131697315 CMS
SOBI, INC $17.6706/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141426269 CMS
EMD Serono, Inc. $13.4506/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120243151 CMS
E.R. Squibb & Sons, L.L.C. $10.5506/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101429362 CMS
Novartis Pharmaceuticals Corporation $16.5406/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087352504 CMS
PFIZER INC. $4,110.0006/13/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131481074 CMS
PFIZER INC. $125.0006/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131481078 CMS
PFIZER INC. $1,246.7606/13/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131482135 CMS
Astellas Pharma US Inc $69.9906/12/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139339618 CMS
Astellas Pharma US Inc $69.9906/12/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139339670 CMS
Gilead Sciences, Inc. $13.4906/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133799894 CMS
Janssen Biotech, Inc. $9.8606/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078616042 CMS
Regeneron Healthcare Solutions, Inc. $18.6706/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114261819 CMS
Eisai Inc. $17.8406/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110790304 CMS
Incyte Corporation $20.4306/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141249210 CMS
Adaptive Biotechnologies Corporation $22.3606/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150261942 CMS
PFIZER INC. $5,109.5006/05/2024 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131481090 CMS
EMD Serono, Inc. $22.7906/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120229154 CMS
Astellas Pharma Global Development $25.0005/31/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132966847 CMS
Astellas Pharma Global Development $1,750.0005/31/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132966849 CMS
Astellas Pharma Global Development $106.7405/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132966863 CMS
Astellas Pharma Global Development $205.0205/31/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132966871 CMS
Aveo Pharmaceuticals, Inc. $1,820.0005/30/2024 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143488920 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,918.16 112
PY2020 $416.46 21
PY2021 $1,097.44 7
PY2022 $559.73 14
PY2023 $7,404.42 35
PY2024 $46,648.31 156
PY2025 $108,457.62 183

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $629,363.18 14
PY2024 Principal investigator $1,437,660.40 14
PY2023 Principal investigator $1,901,163.28 18
PY2022 Principal investigator $1,083,381.09 25
PY2021 Principal investigator $702,831.14 14
PY2020 Principal investigator $337,920.53 171
PY2019 Principal investigator $180,948.20 161

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

14 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $11,215.36 12/31/2025 Covered Recipient Teaching Hospital
Parkview Hospital
A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy versus Perioperative Placebo Neoadjuvant Chemotherapy in Cisplatin-Eligible Participants with Muscle-invasive Bladder Cancer KEYNOTE- No dispute reported 06/30/2026 1232927567
Principal investigator 1 Merck Sharp & Dohme LLC $22,623.22 12/31/2025 Covered Recipient Teaching Hospital
Parkview Hospital
A Randomized Phase 3 Study Evaluating Cystectomy with Perioperative Pembrolizumab and Cystectomy with Perioperative Enfortumab Vedotin and Pembrolizumab versus Cystectomy Alone in Participants who are Cisplatin-Ineligible or Decline Cisplatin with Muscle- No dispute reported 06/30/2026 1232927745
Principal investigator 1 Merck Sharp & Dohme LLC $11,878.00 12/31/2025 Covered Recipient Teaching Hospital
Parkview Hospital
An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib MK-7902 vs Cabozantinib for Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1,L1 Therapy No dispute reported 06/30/2026 1232931266
Principal investigator 1 Merck Sharp & Dohme LLC $10,951.29 12/31/2025 Covered Recipient Teaching Hospital
Parkview Hospital
An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Belzutifan MK-6482 and Lenvatinib MK-7902, or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as First No dispute reported 06/30/2026 1232934652
Principal investigator 1 Merck Sharp & Dohme LLC $200,076.27 12/31/2025 Covered Recipient Teaching Hospital
Parkview Hospital
An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Belzutifan MK-6482 and Lenvatinib MK-7902, or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as First No dispute reported 06/30/2026 1232934654
Principal investigator 1 Merck Sharp & Dohme LLC $11,014.20 12/31/2025 Covered Recipient Teaching Hospital
Parkview Hospital
A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan MK-6482 Plus Pembrolizumab MK-3475 Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma ccRCC Post Neph No dispute reported 06/30/2026 1232934722
Principal investigator 1 Merck Sharp & Dohme LLC $144,347.65 12/23/2025 Covered Recipient Teaching Hospital
Parkview Hospital
A Randomized Phase 3 Study Evaluating Cystectomy with Perioperative Pembrolizumab and Cystectomy with Perioperative Enfortumab Vedotin and Pembrolizumab versus Cystectomy Alone in Participants who are Cisplatin-Ineligible or Decline Cisplatin with Muscle- No dispute reported 06/30/2026 1232927701
Principal investigator 1 Merck Sharp & Dohme LLC $38,970.29 12/15/2025 Covered Recipient Teaching Hospital
Parkview Hospital
An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib MK-7902 vs Cabozantinib for Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1,L1 Therapy No dispute reported 06/30/2026 1232931264
Principal investigator 1 Merck Sharp & Dohme LLC $70,161.53 12/01/2025 Covered Recipient Teaching Hospital
Parkview Hospital
A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy versus Perioperative Placebo Neoadjuvant Chemotherapy in Cisplatin-Eligible Participants with Muscle-invasive Bladder Cancer KEYNOTE- No dispute reported 06/30/2026 1232927397
Principal investigator 1 Merck Sharp & Dohme LLC $43,287.60 11/24/2025 Covered Recipient Teaching Hospital
Parkview Hospital
A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan MK-6482 Plus Pembrolizumab MK-3475 Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma ccRCC Post Neph No dispute reported 06/30/2026 1232934720
Principal investigator 1 Organon Llc $530.67 09/24/2025 Covered Recipient Teaching Hospital
Parkview Hospital
3475-866 No dispute reported 06/30/2026 1173042152
Principal investigator 1 Organon Llc $1,061.34 09/19/2025 Covered Recipient Teaching Hospital
Parkview Hospital
3475-866 No dispute reported 06/30/2026 1173042622
Principal investigator 1 Merck Sharp & Dohme LLC $17,691.36 08/31/2025 Covered Recipient Teaching Hospital
Parkview Hospital
A Randomized Phase 3 Study Evaluating Cystectomy with Perioperative Pembrolizumab and Cystectomy with Perioperative Enfortumab Vedotin and Pembrolizumab versus Cystectomy Alone in Participants who are Cisplatin-Ineligible or Decline Cisplatin with Muscle- No dispute reported 06/30/2026 1232927747
Principal investigator 1 Merck Sharp & Dohme LLC $45,554.40 05/14/2025 Covered Recipient Teaching Hospital
Parkview Hospital
An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Belzutifan MK-6482 and Lenvatinib MK-7902, or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as First No dispute reported 06/30/2026 1232934650